Interleukin-12 and Interleukin-4 Levels of Multibacillary Leprosy Patients Before and After Rifampicine Ofloxacine Minocycline Combined Therapy
American Journal of Clinical and Experimental Medicine
Volume 5, Issue 4, July 2017, Pages: 134-137
Received: Feb. 18, 2017; Accepted: Mar. 6, 2017; Published: Jul. 3, 2017
Views 1870      Downloads 53
Authors
Suci Budhiani, Department of Dermatology and Venereology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Sri Vitayani Muchtar, Department of Dermatology and Venereology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Safruddin Amin, Department of Dermatology and Venereology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Article Tools
Follow on us
Abstract
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, which is an obligate intracellular bacteria. This study aims to determine the interleukin-12 and interleukin-4 levels of multibacillary leprosy patients before and after Rifampicine Ofloxacine Minocycline (ROM) combined therapy for three months. The research used an analytic observational design with the prospective cohort study pre and post treatment method. The samples were taken at the polyclinic of Skin Treatment Central Public hospital and Ibnu Sina hospital. Samples examination was conducted in the NECHRI laboratory, Hasanuddin University Teaching hospital. The samples were ten new patients of MB type leprosy. Blood samples were taken before and after the ROM therapy for three months. The levels of interleukin-12 and interleukin-4 were assessed using the ELISA technique. The results shows that there is no significant change in the levels of interleukin-12 and interleukin-4 in the patients of multibacillary leprosy before and after ROM therapy for three months.
Keywords
Interleukin-12, Interleukin-4, MB Type Leprosy, ROM
To cite this article
Suci Budhiani, Sri Vitayani Muchtar, Safruddin Amin, Interleukin-12 and Interleukin-4 Levels of Multibacillary Leprosy Patients Before and After Rifampicine Ofloxacine Minocycline Combined Therapy, American Journal of Clinical and Experimental Medicine. Vol. 5, No. 4, 2017, pp. 134-137. doi: 10.11648/j.ajcem.20170504.15
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Correa et al. (2012). Epidemiological, clinical, and operational aspects of leprosy patients assisted at a referral service in the state of Maranhao, Brazil. Rev Soc Bras Med Trop 45 (1): 89-94.
[2]
Martins et al. (2012). Pathogen-Specific Epitopes as Epidemiological Tools For Defining The Magnitude of Mycobacterium Leprae Transmission in Areas Endemic for Leprosy. PloSNegl Trop Dis 6(4): e1616.
[3]
Parkash.(2009). Classification of Leprosy IntoMultibacillary and Paucibacillary Groups: An Analysis. FEMS Immunol Med Microbiol 55: 1-5.
[4]
Walker &Lockwood. (2006). The Clinical and Immunological Features of Leprosy. British Medical Bulletin 77 and 78: 103-21.
[5]
Jarduli et al. (2013). Role of HLA, KIR, MICA and Cytokines Genes in Leprosy. Hindawi Publishing Corporation. 1-17.
[6]
Modlin RL. 1994. Th1-Th2 paradigm: insight from leprosy. J Invest Dermatol 102: 828.
[7]
Setia et al. (2011). Is There a Role for Rifampicin, Ofloxacin, and Minocycline (ROM) Therapy in the Treatment of Leprosy? Systematic Review and Meta-Analysis. Trop Med & Intern Health.16: 1541-51.
[8]
Worobec. (2012). Current Approaches and Future Directions in The Treatment of Leprosy. Research and Reports in Trop Med; 3: 79-91.
[9]
Lockwood &Cunha.(2012). Developing New MDT Regimens for MB Patients: Time to Test ROM 12 Month Regimens Globally. Lepr Rev 83: 241-4.
[10]
Noordeen, S. K. (1994) Epidemiology of leprosy. In: Hastings, R. C. & Opromolla, D. V. A. (Eds.) Leprosy. 2nd ed. Edinburgh, Churchill Livingstone.
[11]
Madan et al. (2011). Serum Cytokine Profile in Leprosy and Its Correlation WithClinico-Histopathological Profile. Lepr Rev. 82:371-82.
[12]
Degang et al. (2014). Leprosy as A Model of Immunity. Future Microbiol. 9 (1): 43-54.
[13]
Stefani M, Martelli C. M., Gillis T. P., Kranhenbuhl J. L. (2003). In situ type 1 cytokine gene expression and mechanism associated with early leprosy progression. JID. 188: 1024-1030.
[14]
Moubasher, A. E. A., Kamel, N. A., Zedan, H. & Raheem, D. E. A. (1998a). Cytokines in leprosy. Int J dermatol. 37: 733-40.
[15]
Moubasher, A. E. A., Kamel, N. A., Zedan, H. & Raheem, D. E. A. (1998b). Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy. Int J Dermatol. 37: 741-6.
[16]
Bandjar.(2015). Analisis Titer Interleukin-12 dan Interleukin-4 Pada Penderita Kusta Multibasiler Pre dan Post Terapi 3 Bulan Dengan Multidrug-Therapy-World Health Organization. Makassar: Program Pascasarjan Universitas Hasanuddin.
[17]
Misra N, Murtaza A, Walker B, Narayan N, Misra R. S., Ramesh V. (1995). Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae. Immunology. 86: 97-103.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186